Previous Article | Next Article ![]()
Eukaryotic Cell, July 2005, p. 1211-1220, Vol. 4, No. 7
1535-9778/05/$08.00+0 doi:10.1128/EC.4.7.1211-1220.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Veterinary Pathobiology, College of Veterinary Medicine,1 Faculty of Genetics Program, Texas A&M University, 4467 TAMU, College Station, Texas 77840-44672
Received 20 March 2005/ Accepted 9 May 2005
|
|
|---|
|
|
|---|
During fatty acid synthesis, the fatty acyl chain needs to be attached to the holo-ACP at the prosthetic 4'-phosphopantetheinyl moiety. However, newly synthesized ACP enzymes or domains are apoproteins that lack the phosphopantetheinyl moiety. The phosphopantetheinyl moiety is posttranslationally transferred from CoA to a Ser residue in the ACP by a phosphopantetheinyl transferase (PPTase) (EC 2.7.8.7
[EC]
) (Fig. 1). There are two major types of PPTases. The holo-ACP synthase (ACPS)-type PPTases are typically specific to the type II FAS or polyketide synthase (PKS) in bacteria, e.g., Escherichia coli AcpS (21, 22). The surfactin production element (SFP)-type enzymes are mostly specific to type I FAS, PKS, or nonribosomal peptide synthase, such as the Bacillus subtilis SFP, yeast Lys5, and human PPTase (19, 26, 28, 30). The FAS
-subunit (FAS2) in fungi also contains an ACPS-type PPTase domain and is sometimes referred to as a third type of PPTase (10, 27).
![]() View larger version (16K): [in a new window] |
FIG. 1. PPTases synthesize holo-ACP by transferring the phosphopantetheinyl moiety from CoA to apo-ACP (A). The phosphopantetheinyl moiety is attached to the Ser residue of ACP (B).
|
In this study, we have identified both SFP and ACPS types of PPTases that may be responsible for activating type I and II apicomplexan ACPs, respectively, from three major groups of apicomplexans (i.e., P. falciparum, T. gondii, and C. parvum). Bioinformatics analyses suggest that these two types of apicomplexan PPTases may have different evolutionary origins. The SFP-type PPTases are more closely related to animal and fungal PPTases, while the ACPS-type enzymes were probably acquired from a proteobacterium. To further confirm the function of apicomplexan PPTases, we have also cloned and expressed the PPTase from C. parvum and detailed its enzymatic features in activating recombinant CpFAS1 ACP domains. The expression and protein localization of CpSFP-PPT have been investigated using real-time PCR and immunofluorescence microscopy.
|
|
|---|
Apicomplexan PPTases were used as queries to search protein databases, including all nonredundant GenBank CDS translations plus RefSeq Proteins plus PDB plus SwissProt plus PIR plus PRF at the National Center for Biotechnology Information using the PSI-BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/) (3). Four iterative PSI-BLAST searches were performed for each protein (matrix = BLOSUM62; gap penalties: existence = 11 and extension = 1). Only sequences with E-values lower than 1 x 104 were retrieved for further analysis. Protein multiple sequence alignments were performed using a ClustalW algorithm, and apparent mistakes in alignments were corrected based upon visual inspections. Conserved motifs were determined from protein alignments (see protein alignments in the supplemental material), and block logos were derived from position-specific scoring matrices (PSSM) at the BLOCKS server (http://blocks.fhcrc.org/blocks) (15).
Only amino acid positions that could be unambiguously aligned were selected for phylogenetic analyses (see protein alignments in the supplemental material). Maximum likelihood (ML) trees were constructed using the PROML program distributed in the PHYLIP package (http://evolution.gs.washington.edu/phylip.html). The JTT model of amino acid substitution (18) was used in ML analysis with the consideration of among-site heterogeneity using the fraction of invariance plus a four-rate
-distribution model (JTT-f +
+ Inv). Sequence input orders were randomized with 10 jumps, and global rearrangements were enabled during the tree searches. Missing parameters required by the PROML program were estimated by the Tree-Puzzle v5.2 program (34). In addition, ML trees were also reconstructed using a Bayesian inference method using the same model of amino acid substitutions (i.e., JTT-f +
+ Inv) (17). A total of 500,000 generations of searches were performed with four chains simultaneously running, and the current trees were saved every 100 generations. Posterior probabilities at tree nodes were obtained by calculating consensus trees from 4,000 Bayesian inference trees written after the ML sums converged.
Gene expression pattern and protein localization of CpSFP-PPT in C. parvum. The CpSFP-PPT gene expression pattern during the parasite complex life cycle was analyzed by real-time quantitative RT-PCR (qRT-PCR). Total RNA was isolated from different C. parvum (IOWA strain) life cycle stages (i.e., oocysts, sporozoites, intracellular stages cultured in HCT-8 cells for 6, 12, 24, 36, 48, 60, and 72 h) and uninfected host cells using an RNeasy isolation kit (QIAGEN) (7, 24). Since host cell RNA was present in intracellular samples, only the relative level of CpSFP-PPT transcripts was determined in comparison to that of C. parvum 18S rRNA for each sample. Real-time qRT-PCR analyses were performed using the SYBR-green-based iScript One-Step RT-PCR kit (Bio-Rad) and primers specific to CpSFP-PPT (301F, 5'-TCG GAA AGT GAT TCA TTA CTG C-3'; and 421R, 5'-CTC TGG AAG GTG ATA ACT CGG-3') and 18S rRNA (995F, 5'-TAG AGA TTG GAG GTT GTT CCT-3'; and 1206R, 5'-CTC CAC CAA CTA AGA ACG GCC-3') (1), respectively. Reactions containing 20 ng of total RNA and 0.2 µM specified primers were first incubated at 48°C for 30 min to synthesize cDNA, heated at 95°C for 15 min to inactivate reverse transcriptase, and then subjected to 45 thermal cycles (95°C, 20 s; 50°C, 30 s; and 72°C, 30 s) of PCR amplification using an iCycler iQ real-time PCR detection system (Bio-Rad). Each reaction contained at least three replicates. Under the specified conditions and based on annealing curve analysis, each pair of primers produced only one amplicon from samples containing parasite RNA but no products from total RNA isolated from uninfected host cells. Standard curves for both pairs of primers were determined using serially diluted DNA templates in real-time PCR analysis, followed by linear regression to determine needed parameters (curve slopes and intersections). Based on the standard curves, the amounts of CpSFP-PPT transcripts and 18S rRNA in every sample were calculated. The level of CpSFP-PPT transcripts in each sample was then normalized using that of 18S as a control (i.e., expressed as a ratio between levels of CpSFP-PPT and 18S rRNA). Finally, the relative level of CpSFP-PPT transcripts in each developmental stage was plotted relative to the mean level of all samples (i.e., ratio between individual normalized level and the overall mean).
For producing polyclonal antibodies to CpSFP-PPT, a short peptide corresponding to the CpSFP-PPT amino acid positions at 81 to 100 (CSPKQVKIIREKGMKPYFKY) was synthesized, cross-linked to keyhole limpet hemocyanin, and used to immunize two pathogen-free rabbits three times according to standard protocols at a commercial source (Alpha Diagnostic International). The preimmune sera and antisera were evaluated using enzyme-linked immunosorbent assay, immunofluorescence microscopy, and Western blot analysis to determine their specificities and titers.
In Western blot analysis, C. parvum sporozoites were prepared by excystation from fresh oocysts as previously described (24). Sporozoites were lysed in 1x sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer containing 1x protease inhibitor cocktail (Sigma), fractionated by 10% SDS-PAGE (
2 x 107 sporozoites/lane), and transferred to a nitrocellulose membrane. Both rabbit preimmune serum and polyclonal antibody to CpSFP-PPT (1:1,000 dilution) were incubated with membrane blots, which were in turn detected with an Immuno-Star-AP chemiluminescent kit (Bio-Rad).
To detect CpSFP-PPT in parasite cells by immunofluorescence microscopy, C. parvum sporozoites and intracellular stages infecting HCT-8 monolayers (cultured on glass coverslips) were fixed in phosphate-buffered saline (PBS)-formalin (10%), washed with PBS and water, extracted with cold methanol (20°C for 10 min) and 0.1% Triton X-100 (5 min, all at room temperature unless otherwise specified), respectively, and blocked with 5% bovine serum albumin (BSA)-PBS. Samples were then incubated with rabbit preimmune or antiserum (1:1,000 dilution) in 1% BSA-PBS, washed with PBS, and then incubated with a tetramethyl rhodamine isothiocyanate-labeled monoclonal antibody to rabbit immunoglobulin G (Sigma). Immunolabeled samples were mounted using a SlowFade antifade medium containing 4',6'-diamidino-2-phenylindole for DNA counterstaining (Molecular Probes).
Expression of recombinant CpSFP-PPT and ACP domains. The CpSFP-PPT gene was first cloned from parasite cDNA for expression in several commonly used bacterial fusion systems (e.g., pET-based T7-tag, His-tag, and S-tag fusions). However, either the expression was unsuccessful or the expression level was too low to be useful for biochemical assays. The unsuccessful expression of CpSFP-PPT was probably due to the extremely biased codon usages between the AT-rich C. parvum and Escherichia coli genes. To overcome the difficulties in protein expression, we used a PCR-based gene synthesis approach to reconstruct an artificial CpSFP-PPT gene based on E. coli class II codon frequencies. Briefly, a total number of 40 overlapping oligonucleotides (32 to 52 bases) were "reverse translated" from the CpSFP-PPT protein sequence at the "DNAWorks" oligonucleotide design server (http://molbio.info.nih.gov/dnaworks) (16). BamHI restriction sites were avoided in the synthetic gene but added to the 5' and 3' ends. A two-step PCR approach was employed. The first PCR contained all 40 oligonucleotides (0.2 µM each), and a 15-cycle amplification by Pfu DNA polymerase produced a smear of products. The second 20-cycle amplification step used the outer two oligonucleotides (0.2 µM) as primers and 1 µl of product from the first PCR as a template and yielded a single product. The synthetic gene was purified from an agarose gel and cloned into the pCR-Blunt II-TOPO vector. After its identity was confirmed by sequencing, the synthetic CpSFP-PPT gene was released by BamHI and inserted into the pET-29a vector with an S tag fused at the N terminus. Expression of S-tag-fused CpSFP-PPT (S-CpSFP-PPT) protein was carried out in a BL21(DE3) E. coli strain as recommended by the manufacturer (Novagen). The S-CpSFP-PPT protein was purified from bacteria using an S-tag thrombin purification kit, in which the fusion protein was isolated by S-protein agarose columns and the "native" CpSFP-PPT portion was released from the columns by digestion with thrombin.
The ACP domains within the loading unit (CpACP1) and elongation module 1 (CpACP2) of CpFAS1 were engineered into the pET24a (Novagen) and pMAL-c2x (New England Biolabs) vectors, respectively, as previously reported (44). The expression of T7-tag-fused CpACP1 (T7-CpACP1) or maltose-binding protein (MBP)-fused CpACP2 (MBP-CpACP2) was carried out in E. coli Rosetta (DE3) or Rosetta strains. Recombinant T7-CpACP1 and MBP-CpACP2 were purified using a T7-tag affinity purification kit (Novagen) or an amylose resin-based affinity purification kit (New England Biolabs), respectively.
Enzyme assays. The activity of recombinant CpSFP-PPT was assayed using recombinant apo-T7-CpACP1 or apo-MBP-CpACP2 to receive the phosphopantetheinyl moiety from CoA or acetyl-CoA. Typical assay systems were performed in 100 µl Tris-HCl solution (75 mM; pH 7.0) containing MgCl2 (0.0039 to 20 mM), acetyl-CoA (0.39 to 200 µM) (or CoA), apo-ACP (0.85 to 1 µg), and CpSFP-PPT (100 ng) at 37°C for specified time periods (19). After determining that CpSFP-PPT could maintain linear activity for up to 20 min, we assayed the enzyme kinetics with 10-min reactions using [1-14C]acetyl-CoA and MBP-CpACP2 (5.0 µM) as cosubstrates. Reactions were stopped by adding 1 ml trichloroacetic acid (10%) and 25 µl BSA (2%) as a protein carrier (13, 30). Quenched reactions were incubated on ice for 5 min and centrifuged at 10,000 x g for 10 min. Protein pellets were washed three times with 1 ml trichloroacetic acid (10%), dissolved in 150 µl formic acid, and transferred into 10 ml scintillation cocktail (Sigma) for counting of radioactivity. For matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS), reaction mixtures containing 0.1 mM acetyl-CoA (or CoA), 1 µg T7-CpACP1, and 1.0 mM MgCl2 were incubated for 30 min at 37°C, from which 20 µl solution from each reaction was removed for SDS-PAGE (20%) analysis, and the remaining 80 µl solution was desalted with a Bio-Gel P-6DG resin (Bio-Rad) for determining the Mr of T7-CpACP1 by MALDI-TOF MS. Reactions for autoradiography followed similar procedures but used [1-14C]acetyl-CoA (0.1 mM) and T7-CpACP1 or MBP-CpACP2 as substrates. Reactions were fractionated by SDS-PAGE. The radioactivity from the CpSFP-PPT-transferred phosphopantetheinyl moiety on the T7-holo-CpACP1 or MBP-holo-CpACP2 was visualized from dried gels using a FUJI BAS 1800 II PhosphorImager.
Activation of T7-CpACP1 by coexpression with CpSFP-PPT in bacteria. For coexpression S-CpSFP-PPT and T7-CpACP1, we first isolated the pRIG-derived pRARE plasmid from Rosetta bacteria (4) and prepared a blunt-ended plasmid by PCR (primers: 5'-ACT AGT AAC GGC CGC CAG TGT GC-3' and 5'-AGT GGA TCC GAG CTC GGT ACC AAG-3'). Second, the S-CpSFP-PPT construct, including the complete T7 promoter and transcriptional terminator, was amplified from the pET29a-CpSFP-PPT vector (primers: 5'-CTC CTT TCA GCA AAA AAC CCC-3' and 5'-CCC GCG AAA TTA ATA CGA CTC-3'), phosphorylated, and ligated into the linear pRARE vector. The resulting pRARE-CpSFP-PPT construct and the pET24a-T7-CpACP1 vector were sequentially transformed into BL21(DE3) bacteria for coexpressing S-CpSFP-PPT and T7-CpACP1 proteins. In the control experiments, T7-CpACP1 was coexpressed with plain pRARE vector only. T7-CpACP1 proteins coexpressed with S-CpSFP-PPT or pRARE vector only were purified and desalted for the determination of their molecular masses by MALDI-TOF MS analysis.
Nucleotide sequence accession number. Nucleotide sequence data for the CpSFP-PPT gene are available in the EMBL, GenBank, and DDJB databases under the accession number AY856092.
|
|
|---|
![]() View larger version (25K): [in a new window] |
FIG. 2. Comparison of two types of PPTases among apicomplexans and other groups of organisms. SFP-PPTs are present in bacteria, type I FAS-containing apicomplexans, fungi, animals, and plants. Some plant SFP-PPTs may contain an N-terminal mitochondrium-targeting signal (open box in parenthesis). ACPS-PPTs are present in bacteria, plastid-containing apicomplexans, and fungi. Apicomplexan ACPS-PPTs are bifunctional and contain plastid-targeting signals (open box). Fungal ACPS-PPTs are present as a C-terminal domain in the -subunit of fatty acid synthase (FAS2). PSSM logos include two motifs for all PPTases, one specific to SFPs and one for hydrolases.
|
|
View this table: [in a new window] |
TABLE 1. Correlation between the types of PPTases and FAS/PKS in apicomplexans
|
Different evolutionary origins of apicomplexan ACPS-PPT and SFP-PPT.
Although both SFP-PPT and ACPS-PPT are present in the Apicomplexa or even within one species (e.g., T. gondii), these enzymes may have different evolutionary origins based on the phylogeny individually performed for SFP-PPT, ACPS-PPT, and hydrolase protein sequences. Apicomplexan SFP-PPTs are phylogenetically related to animal and some fungal PPTases in maximum-likelihood trees inferred from 30 closely related protein sequences (Fig. 3A). The animals plus apicomplexans plus fungi cluster was subsequently joined by a group of
-proteobacteria. It is noted that plants and some fungi formed two clades separated from the animal clade (Fig. 3A). However, because the resolving power of the SFP-PPT data set was limited by the small number of alignable positions (i.e., 52 amino acids), one could not firmly determine whether the separation among eukaryotic SFP-PPTs (more intriguingly, the separation of different fungal sequences) is caused by the long branch attraction artifact or indeed a result of multiple evolutionary origins of these eukaryotic SFP-PPTs.
![]() View larger version (25K): [in a new window] |
FIG. 3. ML trees inferred from (A) SFP-PPT sequences (30 sequences, 52 positions; lnL = 2132.5); (B) ACPS-PPT sequences (30 sequences, 83 positions; lnL = 3327.5); and (C) metal-dependent hydrolase sequences (32 sequences, 88 positions; lnL = 4264.4). Statistical supporting values are posterior probabilities based on a Bayesian inference method. Only posterior probability values of >70% are shown, and solid dots represent PP values of 95%.
|
-proteobacterial cluster (Fig. 3B). The proteobacterial origin of apicomplexan ACPS-PPTs was further supported by the phylogenetic analysis of the hydrolase domains, in which the apicomplexan clade formed a sister group to the
-, ß-, and
-proteobacterial clade (though paraphyletic to the
-proteobacterial hydrolases) (Fig. 3C).
The unusual two-intron-containing CpSFP-PPT gene is expressed in all parasite life cycle stages.
Among apicomplexan PPTase genes, PfACPS-PPT (NP_702851
[GenBank]
) has recently been annotated by the P. falciparum genome-sequencing consortium. TgACPS-PPT (TgTwinScan_3790) and TgSFP-PPT (contig TGG_995284) were identified from the ToxoDB (Release 3.0; 10x coverage) raw genome sequence data (http://www.toxodb.org) (see TgSFP-PPT and TgACPS-PPT protein sequences in the supplemental material). CpSFP-PPT has been annotated by the C. parvum genome project (EAK89734
[GenBank]
as an intronless gene. However, our sequence analysis of CpSFP-PPT cDNA indicated that this gene is actually interrupted by two introns. The first intron contains multiple stop codons in all three open reading frames. However, the second intron is cryptic, since it contains no stop codon in the open reading frame extended from the second exon, thus misleading the computational prediction of C-terminal amino acids. Introns are not common in C. parvum, and only a few of them are reported (6, 7, 9). The genome-wide analysis suggests that only
5% of C. parvum genes may contain introns (2). Therefore, the presence of two introns in CpSFP-PPT appears to be unusual for this parasite.
In Western blotting analysis of fractionated proteins from C. parvum sporozoites, the rabbit anti-CpSFP-PPT antibodies recognized a major band at
37 kDa (Fig. 4), although a slightly higher minor band (probably caused by nonspecific reactions) was also observed. The detected molecular weight agrees well with the theoretical mass of the CpSFP-PPT protein. Real-time qRT-PCR analysis indicated that the CpSFP-PPT gene is expressed in all C. parvum life cycle stages, suggesting that the activation of ACP domains is a continuous process during parasite development. However, the relative level of CpSFP-PPT transcripts (normalized using the level of 18S rRNA) was slightly higher in sporozoites and intracellular parasites at 12 h postinfection than other stages (Fig. 5). The lowest level of CpSFP-PPT expression was in the oocysts, and correlated with the overall low metabolic activity in this environmental parasite stage (Fig. 5). The low-level expression of CpSFP-PPT in unexcysted oocysts is unlikely to be an experimental artifact caused by poor isolation of oocyst RNA, because a comparable level of 18S rRNA was detected from this sample. The CpSFP-PPT protein was also detected in the cytosol of all parasite life cycle stages by indirect immunofluorescence microscopy (Fig. 6), which agrees with the lack of any signal peptide sequence and is congruent with the cytosolic nature of its substrates (CpFAS1 and CpPKS1) (44).
![]() View larger version (19K): [in a new window] |
FIG. 4. Western blot detection of CpSFP-PPT in total protein extracted from C. parvum sporozoites using a rabbit polyclonal antibody against a synthetic peptide specific to CpSFP-PPT. The negative control used rabbit preimmune serum.
|
![]() View larger version (20K): [in a new window] |
FIG. 5. Relative transcriptional levels of the CpSFP-PPT gene among various C. parvum developmental stages as determined by real-time quantitative RT-PCR. The amount of CpSFP-PPT transcript in each sample was first normalized with that of 18S rRNA. The relative levels of transcripts in all samples were then expressed by comparing their normalized values with the mean value.
|
![]() View larger version (58K): [in a new window] |
FIG. 6. Indirect immunofluorescence microscopic detection of CpSFP-PPT in C. parvum free sporozoites (Spz) and an intracellular developmental stage (a merozoite-containing meront) cultured in HCT-8 cells for 24 h. Samples were labeled with rabbit polyclonal antibody to CpSFP-PPT and TRITC-conjugated antirabbit immunoglobulin G monoclonal antibody that gave a diffused pattern in the cytosol of all samples. Preimmune serum did not label the parasite (data not shown). The nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI). Parasite morphology is shown as differential interference constrast (DIC) images taken from the same microscopic fields. A similar pattern of cytosolic distribution of CpSFP-PPT was observed in other intracellular stages (e.g., 12 to 72 h postinfection) but is not shown here.
|
![]() View larger version (15K): [in a new window] |
FIG. 7. Enzymatic activity of recombinant CpSFP-PPT using [1-14C]acetyl-CoA and MBP-CpACP2 as cosubstrates. (A) Effects of cations (1.0 mM each) on the CpSFP-PPT activities. Inset shows the purified CpSFP-PPT (without S tag) analyzed by SDS-PAGE. (B) Effects of Mg2+ concentrations on the activity of CpSFP-PPT. (C) Enzyme kinetics of CpSFP-PPT determined using various concentrations of [1-14C]acetyl-CoA and 5.0 µM MBP-CpACP2 as cosubstrates. Note: In all samples, bars represent standard-error-of-the-mean values derived from at least three replicated reactions. The data presented here were generated from at least two independent experiments.
|
1.6 min1) and Kcat/Km (0.324 min1 · µM1) were at the low end among the PPTases reported so far (19, 25, 26). The successful transfer of a phosphopantetheine moiety from both acetyl-CoA and CoA to T7-CpACP1 was ultimately confirmed by three different approaches. The presence of a phosphopantetheinyl moiety in holo-ACP proteins was made evident by the differences in molecular masses between holo- and apo-ACP proteins as determined by MALDI-TOF MS analysis (Table 2; Fig. 8A and B) and SDS-PAGE fractionation (Fig. 8C). Radioactive phosphopantetheinyl moieties transferred from acetyl-CoA were detected in T7-CpACP1 and MBP-ACP2 fusion proteins that were treated with CpSFP-PPT by autoradiography but not in the proteins that received no CpSFP-PPT treatment (Fig. 8D).
|
View this table: [in a new window] |
TABLE 2. Determination of molecular masses of recombinant T7-CpACP1 by MALDI-TOF MSa
|
![]() View larger version (30K): [in a new window] |
FIG. 8. Detection of the phosphopantetheinyl moiety from CpSFP-PPT-activated CpFAS1 ACP domains. (A) MALDI-TOF mass spectrum of T7-CpACP1 expressed in bacteria. A single peak at 12,061 Da indicates that all C. parvum T7-CpACP1 proteins were present in apo form. (B) MALDI-TOF mass spectrum of T7-CpACP1 coexpressed with CpSFP-PPT in bacteria. The major peak at 13,471 Da represents holo-T7-CpACP1 ( 78%), while the minor peak with lower molecular mass represents apo-T7-CpACP1 ( 22%). (C) Differentiation between apo- and holo-CpACP1 by SDS-PAGE (20% gel) stained with Coomassie blue. Apo-T7-CpACP1 (lanes 1, 3) migrated slightly faster than holo-T7-CpACP1 that received a phosphopantetheinyl moiety from CoA (lane 2) or acetyl-CoA (lane 4) after CpSFP-PPT treatment. (D) CpSFP-PPT-catalyzed transfer of a phosphopantetheinyl moiety from [1-14C]acetyl-CoA (included in all reactions) to either T7-CpACP1 (lane 3) or MBP-CpACP2 (lane 4) was detected by autoradiography. No radioactivity was detected from these two proteins receiving no CpSFP-PPT treatment (lanes 1 and 2) or from CpSFP-PPT itself (lane 5).
|
|
|
|---|
The two types of apicomplexan PPTases appear to have different evolutionary origins: the SFP-PPTs in C. parvum and T. gondii are closely related to animal and fungal PPTases (Fig. 3A), whereas the ACPS-PPTs in P. falciparum and T. gondii are bacterium-like, probably having been acquired from a proteobacterial ancestor (Fig. 3B and C). The presence of two conserved motifs in both ACPS-PPT and SFP-PPT indicates that the two types of PPTases must have evolved from a common ancestor. The separation between ACPS-PPT and SFP-PPT might have occurred before the emergence of eukaryotes, based on the fact that prokaryotic and eukaryotic sequences are intermixed in both SFP-PPT and ACPS-PPT trees. In addition, apicomplexan SFP-PPTs appear to be more ancient than ACPS-PPTs, since the former (clustered with animals and fungi) were likely eukaryotic descendants, while the latter (bacterium-like) were probably acquired from a proteobacterium by lateral gene transfer after the Apicomplexa diverged from other eukaryotes.
The ability to obtain holo-ACP is critical to the biochemical and pharmaceutical studies of FASs. Bacterial expression systems are commonly used in producing recombinant apicomplexan proteins for functional analysis. Previous studies have shown that recombinant P. falciparum ACP enzymes are mostly in holo form when expressed in E. coli, suggesting bacterial ACPS is capable of activating apicomplexan type II ACP (41). In our previous studies, the 900-kDa CpFAS1 protein has been successfully expressed in bacteria as five individual modules (44). However, the ACP domains were found to be apoenzymes, suggesting that the E. coli ACPS was unable to activate the parasite ACP during expression. This technical obstacle apparently has limited our ability in functional dissection of the unique type I CpFAS1 and CpPKS1 using recombinant proteins. Therefore, the discovery and expression of a functional CpSFP-PPT enzyme clearly indicates that recombinant parasite ACP domains could be activated by CpSFP-PPT, thus clearing the path for the future functional analyses, including the determination of the final product(s), of CpFAS1 and CpPKS1 using recombinant proteins.
Fatty acid synthesis has recently been explored as a novel drug target (14, 32, 40, 42). The ultimate dependency of both type I and II FAS (and PKS) on PPTases for synthesizing holo-ACP, together with the high sequence divergence between apicomplexan and animal PPTases, indicates that PPTases may be explored as promising drug targets for this group of globally important parasites.
This research was supported by a grant from National Institutes of Health (R01 AI44594).
Supplemental material for this article may be found at http://ec.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»